is a therapeutic drug development company. For more information , please visit the Curis
web site at www.

, at CORE Orthopedic Medical Center in Encinitas , CA.9cc
per vertebra treated, with the volume ranging from 0. Orthovita undertakes no obligation to
publicly update any forward-looking statements.

m literature

Curis Presents Study Showing Stimulation of Hair Growth by Small Molecule Hedgehog Pathway Agonist

The terms of the agreement
include Wyeth's right to approve any compounds that Curis will
ultimately develop in this area. designed to demonstrate
that Cortoss is safe and effective for the treatment of osteoporotic
vertebral compression fractures .

photograph poets

We are also evaluating
the requirements for clinical development in hair growth indications
in order to decide on an appropriate strategy for moving this program
forward.com

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements about Curis' drug discovery and development
programs . The study results appear to be consistent with the
results obtained in the prospective vertebroplasty study using Cortoss
conducted in Europe.S.

authors biography

About Curis, Inc. The
Company's technology focus is on regulatory pathways that control
repair and regeneration. Curis has
successfully used this technology and product development approach to
produce several promising drug product candidates in the fields of
cancer (under partnership with Genentech, which also includes a
co-development collaboration between Curis and Genentech for a basal
cell carcinoma product candidate), kidney disease (licensed to Ortho
Biotech, a subsidiary of Johnson + Johnson), neurological disorders
(partnered with Wyeth Pharmaceuticals), hair growth, and
cardiovascular disease. Due to the engineered radiopacity of Cortoss,
extravasations were easily detected intra-operatively and averaged
0.

poets poems

Business Editors/Health Editors

CAMBRIDGE, Mass. Under the terms of the license
agreement, Curis retained the right to develop Hedgehog agonists for
topical treatment to stimulate hair growth.

Curis , Inc. Curis' product development involves the use
of proteins or small molecules to modulate these pathways. The study results
seemed to suggest that a relatively small volume of Cortoss may be
able to reinforce the vertebrae and achieve symptomatic relief, as
compared to the larger volumes reported in the literature for
polymethylmethacrylate (PMMA) bone cement. Our products are used in the regeneration
of bone and soft tissue., to develop and market novel synthetic-based
biomaterial products, and continues to pursue similar relationships
with other companies in biomaterials.

arts poems

These forward looking statements are not guarantees of future
performance and involve risks, uncertainties, assumptions and other
factors that may cause Curis' actual results to be materially
different from those indicated by such forward-looking statements.
The pilot IDE study was intended to provide preliminary
information about the use of Cortoss(R) Synthetic Cortical Bone to
treat osteoporotic vertebral compression fractures . Cortoss appeared to have an
interdigitated fill pattern, which is intended to create trabecular
reinforcement.S.12cc as measured on post-op CT scans.

This press release contains forward -looking statements regarding
Orthovita's current expectations of future events that involve risks
and uncertainties, including, without limitations, our products and
other aspects of our business .

poems arts

In the current study, the small molecule Hedgehog agonist, when
topically formulated and applied to the skin, was able to transition
the hair follicles from the resting phase of the hair cycle to the
growth phase, resulting in pronounced stimulation of hair growth.
Daniel Passeri , President and Chief Executive Officer of Curis,
said, "We are very pleased with these results and with the progress
that has been made in our hair growth program.C. at The Spine Institute at Saint John's Health
Center, Santa Monica, CA, led the study.D. Our longer-term U.

m selected

Rudy Paladini, was awarded the first prize among poster
presentations at the meeting.
Hyun Bae, M.D. A larger, prospective randomized controlled
multi-center IDE study is underway in the U.4cc per
vertebra treated.
clinical development program is focused on our Cortoss(R) Synthetic
Cortical Bone technology platform, which is designed for injections in
osteoporotic spines to treat vertebral compression fractures.

mahon photograph

The report , which was presented by senior author
Dr. Such statements may contain the words "believes", "expects ",
"anticipates", "plans", "seeks", "estimates" or similar expressions. from Wednesday, February 23 , 2005 through Friday, February 25,
2005.

photograph authors

(NASDAQ: CRIS), a therapeutic drug development
company , today announced that Curis scientists have demonstrated that
a small molecule drug compound can induce hair growth in a preclinical
model. The
authors of the study conclude that the topical application of a
Hedgehog agonist may be effective in treating hair disorders, such as
male pattern baldness and female pattern hair loss."
The Hedgehog agonist program was exclusively licensed to Wyeth
Pharmaceuticals in February 2004.
Orthovita works jointly with Kensey Nash Corporation and Angiotech
Pharmaceuticals, Inc.

american photograph

In December 2004, Wyeth approved the
reversion of a group of Hedgehog agonist compounds for use in our hair
program.
Actual results can be affected by a number of important factors
including, among other things: adverse results in Curis' and its
strategic partners' product development programs; difficulties or
delays in obtaining or maintaining required regulatory approvals;
Curis' ability to obtain or maintain the patent and other proprietary
intellectual property protection necessary for the development and
commercialization of products based on its technologies; changes in or
Curis' inability to execute its realigned business strategy; the risk
that Curis does not obtain the additional funding required to conduct
research and development of its product candidates and execute on its
business plan; unplanned cash requirements and expenditures; risks
relating to Curis' ability to enter into and maintain important
strategic partnerships, including its ability to maintain its current
collaboration agreements with Genentech, Ortho and Wyeth; the risk
that competitors will discover and develop signaling pathway-based
therapeutics faster and more successfully that Curis and its
collaborators are able to; and other risk factors identified in Curis'
most recent Annual Report on Form 10-K, Quarterly Report on 10-Q and
any subsequent reports filed with the Securities and Exchange
Commission. Curis disclaims any
intention or obligation to update any of the forward-looking
statements after the date of this press release whether as a result of
new information, future events or otherwise.

Orthovita Reports Cortoss Vertebroplasty Data to be Presented at the American Academy of Orthopedic Surgeons

----

A Prospective Multi-Center Pilot IDE Study on the Use of Cortoss
in Vertebroplasty
- Report on the First 20 Cases at Twelve Months -

Orthovita, Inc. Bae. Our near-term commercial business is based on
our Vitoss(R) Bone Graft Substitute technology platforms, which are
designed to address the non-structural bone graft market by offering
synthetic alternatives to the use of autograft or cadaver-derived bone
material to meet a broad range of orthopedic clinical needs in the
spine, trauma, joint reconstruction, revision surgery and extremities
markets, and Vitagel(TM) Surgical Hemostat, which is a safe adherent
matrix and an impermeable barrier to blood flow.

presents photograph

----

Report wins first prize among poster presentations at annual meeting
of American Academy of Dermatology

Curis, Inc.curis.

Business Editors /Health/Medical Writers
American Academy of Orthopedic Surgeons

MALVERN, Pa. Other investigators included
Philip Maurer, M., Timothy Peppers, M. Securities and
Exchange Commission (SEC), including but not limited to risks
described in our most recently filed Form 10-K under the caption
"Certain Risks Related to Our Business".

authors academy

"In this study, the average volume of Cortoss injected was 1. Factors that may cause such a difference
include, but are not limited to, our dependence on the commercial
success of our approved products, our history of operating losses and
our need for additional funds, our need to obtain and maintain
regulatory approvals to sell our products, the rate at which we invest
in our field sales network, the ability of our field sales network to
generate new sales , our ability to manage commercial scale
manufacturing capability and capacity, risks and uncertainties in
pre-clinical and clinical trial results, market acceptance of our
products, the sales levels of our products, our success in expanding
our commercial product portfolio and distribution channel , research
and development, competition and other risk factors listed from time
to time in reports filed by the Company with the U.

academy selected

The drug compound in the study is a small molecule agonist of the
Hedgehog signaling pathway. In the skin, Hedgehog signaling is
required for hair follicle morphogenesis during development and for
regulating hair follicle growth and cycling in the adult. In addition , any forward-looking statements represent the
Company's views only as of today and should not be relied upon as
representing its views as of any subsequent date. (NASDAQ NM:VITA), a leading developer of
orthopedic biomaterials, today reported that a poster titled "A
Prospective Multi-Center Pilot IDE Study on the use of Cortoss in
Vertebroplasty - Report on the First 20 Cases" will be exhibited at
the American Academy of Orthopedic Surgeons being held in Washington,
D.D. at the Pennsylvania Hospital in Philadelphia, PA,
as well as Erik Westerlund, M. All extravasations were
anatomically close to the vertebra and remained asymptomatic, with no
cardiac or pulmonary emboli observed," said Dr. "A larger,
prospective randomized controlled IDE study to confirm these findings
in under way."

About the Company

Orthovita is a leading biomaterials company with proprietary
technologies for the development and commercialization of synthetic,
biologically active, tissue engineering products for orthopedic and
neurosurgical applications. Such statements are based on
management's current expectations and are subject to a number of
substantial risks and uncertainties that could cause actual results or
timeliness to differ materially from those addressed in the
forward-looking statements.

arts american

The data were presented February 19 at the annual meeting of
the American Academy of Dermatology that is being held in New Orleans
from February 18-22.D.D. and Raymond
Linovitz, M .7cc to 4.S. Further information about
these and other relevant risks and uncertainties may be found in
Orthovita's filings with the SEC, all of which are available from the
SEC as well as other sources.